alexa Treatment Options for HCV Genotype-4
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Treatment Options for HCV Genotype-4

Albenmousa A1*, Al Obary E2 and Bzeizi K1
1Department of Gastroenterology and Hepatology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
2BCPS, Pharmacy Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Corresponding Author : Albenmousa A
Consultant Hepatologist, Department of Gastroenterology and Hepatology
Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Tel: 00966503919429
E-mail: [email protected]
Received: December 08, 2015; Accepted: February 06, 2016; Published: February 12, 2016
Citation: Albenmousa A, Al Obary E, Bzeizi K (2016) Treatment Options for HCV Genotype-4. J Infect Dis Ther 4:266. doi:10.4172/2332-0877.1000266
Copyright: © 2016 Albenmousa A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


For the last three decades, HCV infection had been a challenging health problem due to high prevalence rate, fatal complications and till recently the lack of effective treatment. In the pre directly acting agents (DAAs) era, the interferon-ribavirin based treatment was of limited success in the clearance of the virus compounded by major side effects that caused significant morbidity and poor quality of life lasting several months based on the long duration of treatment. Patients with advanced hepatic fibrosis responded poorly to treatment and were far more susceptible to the side effects which at times proved fatal. The new DAAs with their high potency, tolerability and relative short duration of treatment are transforming the landscape of HCV management. The potential of HCV eradication over the coming decades has become a feasible target in many parts of the world. HCV genotype has always been an important predictor of response and an essential determinant for the duration of treatment. Genotype-4 is the predominant genotype in the Middle East particularly Egypt and Gulf region. Clinical trials on genotype-4 are limited especially in the era of directly acting antiviral agents. This review summarizes the treatment options for HCV genotype-4 infection based on available evidence and international HCV treatment guidelines.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version